Bank of America Corp DE Has $19.98 Million Holdings in Privia Health Group, Inc. (NASDAQ:PRVA)

Bank of America Corp DE raised its stake in Privia Health Group, Inc. (NASDAQ:PRVA) by 5.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,021,763 shares of the company’s stock after buying an additional 49,389 shares during the quarter. Bank of America Corp DE owned 0.85% of Privia Health Group worth $19,975,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its position in shares of Privia Health Group by 1.3% in the 4th quarter. Rhumbline Advisers now owns 287,200 shares of the company’s stock valued at $5,615,000 after acquiring an additional 3,658 shares during the period. Barclays PLC increased its stake in Privia Health Group by 240.3% in the third quarter. Barclays PLC now owns 224,018 shares of the company’s stock valued at $4,079,000 after purchasing an additional 158,188 shares in the last quarter. Choreo LLC increased its stake in Privia Health Group by 8.7% in the fourth quarter. Choreo LLC now owns 21,841 shares of the company’s stock valued at $425,000 after purchasing an additional 1,752 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in Privia Health Group by 8.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,169 shares of the company’s stock worth $140,000 after purchasing an additional 533 shares during the period. Finally, Fifth Third Bancorp boosted its position in shares of Privia Health Group by 38.3% during the fourth quarter. Fifth Third Bancorp now owns 5,105 shares of the company’s stock worth $100,000 after purchasing an additional 1,415 shares in the last quarter. Institutional investors own 94.48% of the company’s stock.

Insider Buying and Selling at Privia Health Group

In other Privia Health Group news, CFO David Mountcastle sold 3,445 shares of the business’s stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total transaction of $80,371.85. Following the transaction, the chief financial officer now owns 176,231 shares of the company’s stock, valued at $4,111,469.23. The trade was a 1.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Parth Mehrotra sold 15,100 shares of the firm’s stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total transaction of $352,283.00. Following the completion of the transaction, the chief executive officer now directly owns 454,281 shares of the company’s stock, valued at $10,598,375.73. This represents a 3.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 51,579 shares of company stock worth $1,226,367. Insiders own 10.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on PRVA. Piper Sandler upped their price objective on shares of Privia Health Group from $25.00 to $40.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. Canaccord Genuity Group increased their price target on Privia Health Group from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, February 28th. JMP Securities reiterated a “market outperform” rating and set a $29.00 price objective on shares of Privia Health Group in a report on Monday, April 28th. Robert W. Baird increased their target price on Privia Health Group from $24.00 to $26.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 15th. Finally, Barclays raised their target price on shares of Privia Health Group from $21.00 to $23.00 and gave the stock an “equal weight” rating in a report on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $27.38.

Privia Health Group Stock Down 0.1%

Shares of PRVA opened at $25.00 on Tuesday. Privia Health Group, Inc. has a twelve month low of $15.92 and a twelve month high of $26.09. The stock has a market capitalization of $3.05 billion, a P/E ratio of 250.03, a P/E/G ratio of 3.47 and a beta of 0.87. The company has a 50 day moving average of $23.38 and a 200-day moving average of $22.61.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.